| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10076555 | CLIVUNEL INC | Methods of inducing melanogenesis in a subject |
Feb, 2025
(1 year, 4 months from now) | |
| US8334265 | CLIVUNEL INC | Method of treatment of photodermatoses |
Mar, 2029
(5 years from now) | |
Scenesse is owned by Clivunel Inc.
Scenesse contains Afamelanotide.
Scenesse has a total of 2 drug patents out of which 0 drug patents have expired.
Scenesse was authorised for market use on 08 October, 2019.
Scenesse is available in implant;subcutaneous dosage forms.
Scenesse can be used as increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (epp).
Drug patent challenges can be filed against Scenesse from 2023-10-09.
The generics of Scenesse are possible to be released after 11 March, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Oct 8, 2026 |
| New Chemical Entity Exclusivity (NCE) | Oct 8, 2024 |
Drugs and Companies using AFAMELANOTIDE ingredient
NCE-1 date: 2023-10-09
Market Authorisation Date: 08 October, 2019
Treatment: Increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (epp)
Dosage: IMPLANT;SUBCUTANEOUS
SCENESSE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic